GLP-1tirzepatideheart failurent-probnpmeta-analysis

Tirzepatide meta-analysis reports 34% hsCRP drop in heart failure patients

Pooled data from seven studies and 5,406 participants also showed NT-proBNP fell 17.6 percent versus placebo or standard care.

By Maren Holt · Senior Reporter, GLP-1

Oct 12 20:00 ETSource: The Journal of clinical endocrinology and metabolism

The wire

01The systematic review in JCEM pooled five randomized trials and two observational studies, finding hsCRP down 34.3 percent and NT-proBNP down 17.6 percent with tirzepatide, with moderate GRADE certainty.
02Clinicians treating HFpEF with obesity now have synthesized biomarker evidence alongside SUMMIT's 5.1-point KCCQ-CSS and 15.8-metre 6-minute walk gains.
03Renal findings, including eGFR preservation of 2.90 mL/min/1.73 m2 per year and a 25 percent albuminuria reduction, come from single-trial data the authors call hypothesis-generating pending dedicated heart failure trials.

From the source

Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis
The Journal of clinical endocrinology and metabolism · 2026 Oct 13 · Eisa N, Khoury M et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42867450/